Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 14/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464269 | 0.92 | CYP19A1 (0.34) | OXTRAVPR1ACRHR1CYP19A1 | |
| SCHEMBL4461912 | 0.87 | OXTR (0.33) | OXTRAVPR1AAVPR2NNMTCYP19A1 | |
| SCHEMBL4459564 | 0.84 | CYP19A1 (0.36) | OXTRCRHR1CYP19A1 | |
| SCHEMBL4461775 | 0.81 | KDM4E (0.33) | OXTRCYP19A1 | |
| SCHEMBL4470602 | 0.80 | KCNA5 (0.35) | OXTRCRHR1CYP19A1 | |
| SCHEMBL4453034 | 0.76 | KCNA5 (0.33) | SMN1; SMN2CYP19A1 | |
| SCHEMBL4462686 | 0.74 | CYP19A1 (0.40) | OXTRCRHR1CYP19A1 | |
| SCHEMBL4469190 | 0.71 | CYP19A1 (0.36) | OXTRCYP19A1 | |
| SCHEMBL4464219 | 0.70 | CYP19A1 (0.41) | OXTRAVPR1ACYP19A1 | |
| SCHEMBL14435718 | 0.70 | PDE4D (0.37) | OXTRAVPR1ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | OXTR 2684/4885AVPR1A 2586/4885CRHR1 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.